...
首页> 外文期刊>Leukemia and lymphoma >Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis
【24h】

Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis

机译:阿尔伯塔省北部或南部弥漫性大B细胞淋巴瘤使用不同抢救治疗强度的比较效果分析:工具变量分析

获取原文
获取原文并翻译 | 示例
           

摘要

To date, no clinical trial has addressed salvage therapy intensity for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We sought to determine whether the more intensive salvage chemotherapy approach used in Southern Alberta (SAB) compared to the conventional dose salvage approach used in Northern Alberta (NAB) affects the rates of autologous stem cell transplant (ASCT) and survival in patients with relapsed DLBCL. Using instrumental variable analysis, we examined 147 consecutive patients with relapsed/refractory DLBCL from 2004 to 2010 who received salvage therapy in SAB (n = 70) or NAB (n = 77). Patients treated in SAB had higher rates of: salvage chemotherapy response (85.0% vs. 54.0%, p < 0.001), ASCT (61.4% vs. 41.6%, p = 0.016) and 4-year overall survival (41% vs. 20%, p = 0.002) than those in NAB, respectively. This study supports the hypothesis that selective use of intensive salvage chemotherapy leads to higher rates of ASCT and survival in this population.
机译:迄今为止,尚无临床试验解决复发/难治性弥漫性大B细胞淋巴瘤(DLBCL)的挽救治疗强度。我们试图确定与在艾伯塔省北部使用的常规剂量抢救方法相比,在艾伯塔省南部(SAB)进行的更密集的挽救性化疗方法是否会影响自体干细胞移植(ASCT)的速率和复发性DLBCL患者的生存率。使用工具变量分析,我们检查了2004年至2010年连续147例接受SAB(n = 70)或NAB(n = 77)挽救治疗的复发/难治性DLBCL患者。在SAB中接受治疗的患者具有更高的发生率:挽救性化疗反应(85.0%对54.0%,p <0.001),ASCT(61.4%对41.6%,p = 0.016)和4年总生存率(41%对20) %,p = 0.002)。这项研究支持以下假设:选择性使用强化抢救化疗可提高该人群的ASCT率和生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号